JPH05504774A - エイズ治療を増進するためのメタロポルフィリン類の使用 - Google Patents

エイズ治療を増進するためのメタロポルフィリン類の使用

Info

Publication number
JPH05504774A
JPH05504774A JP3514118A JP51411891A JPH05504774A JP H05504774 A JPH05504774 A JP H05504774A JP 3514118 A JP3514118 A JP 3514118A JP 51411891 A JP51411891 A JP 51411891A JP H05504774 A JPH05504774 A JP H05504774A
Authority
JP
Japan
Prior art keywords
heme
azt
acid addition
treatment
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3514118A
Other languages
English (en)
Japanese (ja)
Inventor
カパス，アタラー
レヴェレ，リチャード　ディ．
アブラハム，ネイダー　ジイ．
ブチャー，ドリス　ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JPH05504774A publication Critical patent/JPH05504774A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP3514118A 1990-07-31 1991-07-25 エイズ治療を増進するためのメタロポルフィリン類の使用 Pending JPH05504774A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56019190A 1990-07-31 1990-07-31
US560,191 1990-07-31
US73509091A 1991-07-24 1991-07-24
US735,090 1991-07-24

Publications (1)

Publication Number Publication Date
JPH05504774A true JPH05504774A (ja) 1993-07-22

Family

ID=27072276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3514118A Pending JPH05504774A (ja) 1990-07-31 1991-07-25 エイズ治療を増進するためのメタロポルフィリン類の使用

Country Status (5)

Country Link
EP (1) EP0543902A4 (de)
JP (1) JPH05504774A (de)
AU (1) AU645131B2 (de)
CA (1) CA2088593A1 (de)
WO (1) WO1992002242A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005285A1 (en) * 1992-09-03 1994-03-17 The Regents Of The University Of California Metallo porphyrin compositions
AU1296795A (en) * 1993-12-28 1995-07-17 New York Blood Center, Inc., The Methods for preventing or treating hiv-1 or hiv-2 infection
TW247876B (en) 1993-12-28 1995-05-21 New York Blood Ct Inc Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
EP0939644B1 (de) * 1996-08-27 2004-01-14 Hemosol Inc. Gesteigerte stimulation der erythropoesis
AU765856B2 (en) * 1996-08-27 2003-10-02 Hemosol Inc. Enhanced stimulation of erythropoiesis
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
AU2003258604A1 (en) * 2002-03-28 2003-10-13 Exponential Biotherapies, Inc. Oxygenating agents for enhancing host responses to microbial infections
GB0519169D0 (en) 2005-09-21 2005-10-26 Leuven K U Res & Dev Novel anti-viral strategy
RU2475498C1 (ru) * 2011-11-17 2013-02-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новые производные гемина с антибактериальной и противовирусной активностью

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049493A (en) * 1987-10-23 1991-09-17 California Institute Of Technology Enhancement of cell growth by expression of a cloned hemoglobin gene
EP0337598A3 (de) * 1988-02-26 1991-07-03 Georgia State University Foundation, Inc. Verwendung von Porphyrinen und Metalloporphyrinen zur Behandlung von durch HIV verursachten Krankheiten
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions

Also Published As

Publication number Publication date
WO1992002242A1 (en) 1992-02-20
EP0543902A1 (de) 1993-06-02
CA2088593A1 (en) 1992-02-01
EP0543902A4 (en) 1993-10-27
AU645131B2 (en) 1994-01-06
AU8410491A (en) 1992-03-02

Similar Documents

Publication Publication Date Title
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
Sommadossi et al. Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity
Mitsuya et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Montefiori et al. Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro
Soudeyns et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
Lin et al. Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol
Nakashima et al. Purification and characterization of an avian myeloblastosis and human immunodeficiency virus reverse transcriptase inhibitor, sulfated polysaccharides extracted from sea algae
Nakashima et al. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro
Hammer et al. Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro
US5622959A (en) Method of treating retroviral infections in mammals
WO1992021368A1 (en) Composition and method for disease treatment
Kageyama et al. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations
Wood et al. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study
NAKASHIMA et al. A new anti-human immunodeficiency virus substance, glycyrrhizin sulfate; endowment of glycyrrhizin with reverse transcriptase-inhibitory activity by chemical modification
Turano et al. Inhibitory effect of papaverine on HIV replication in vitro
JPH05504774A (ja) エイズ治療を増進するためのメタロポルフィリン類の使用
Tochikura et al. A biological response modifier, PSK, inhibits human immunodeficiency virus infection in vitro
Vogt et al. Synergistic interaction of 2′, 3′-dideoxycytidine and recombinant interferon-α-A on replication of human immunodeficiency virus type 1
Lacaille et al. Persistent Mycobacterium marinum infection in a child with probable visceral involvement
JPH11139977A (ja) Ｎｅｆ作用抑制剤
DE68914990T2 (de) Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo.
Sheehy et al. Supplemental sulfone (dapsone) therapy: use in treatment of chloroquine-resistant falciparum malaria
KR20000069296A (ko) 항바이러스 활성을 갖는 살비아 종의 추출물
Katabira et al. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial.
JPH02145527A (ja) エイズ治療および阻害剤